Shattuck Labs, Inc. filings document the regulatory disclosures of a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases. Its 8-K reports cover operating results, financial condition, clinical-program updates for SL-325, material agreements, and capital-structure matters involving its Nasdaq-listed common stock.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, stockholder proposal deadlines, board composition changes, and executive-compensation or equity-award topics. Registration and offering-related disclosures include common stock financing arrangements, Form S-3 materials, and at-the-market offering mechanics.
Shattuck Labs, Inc. Chief Business Officer Casi DeYoung reported a small share disposition in company stock. On 01/25/2026, DeYoung disposed of 2,286 shares of Shattuck Labs common stock at a price of $4.15 per share in a transaction coded "F," which typically reflects a disposition reported on a Form 4. Following this transaction, DeYoung directly beneficially owned 73,480 shares of Shattuck Labs common stock.
Shattuck Labs Chief Financial Officer Andrew R. Neill reported a small change in his holdings of Shattuck Labs, Inc. common stock. On January 25, 2026, he disposed of 2,589 shares of common stock in a transaction reported under SEC transaction code "F" at a reported price of $4.15 per share. Following this transaction, Neill beneficially owns 228,224 shares of Shattuck Labs common stock, held directly.
Shattuck Labs, Inc. entered into a sales agreement with Leerink Partners LLC to sell up to $75,000,000 of its common stock through an at-the-market equity program under an effective Form S-3 shelf registration. Shares may be sold from time to time at market prices, and the company is not obligated to sell any amount and can suspend or terminate the program.
Leerink Partners will act as sales agent and earn a commission of up to 3.0% of the gross sales price of any shares sold, plus reimbursed expenses. Shattuck Labs plans to use any net proceeds to fund ongoing and planned clinical trials, develop additional product candidates, and for working capital and general corporate purposes.
Shattuck Labs, Inc. is establishing an at-the-market stock offering program, registering shares of its common stock with an aggregate offering price of up to $75,000,000. The shares may be sold from time to time through Leerink Partners, which will act as sales agent on a commercially reasonable efforts basis and receive a commission of up to 3.0% of the gross sales price per share.
The company’s common stock trades on the Nasdaq Global Select Market under the symbol STTK, with a last reported sale price of $4.44 per share on January 21, 2026. Shattuck Labs is a biotechnology company developing treatments for inflammatory and immune‑mediated diseases, including its lead antibody program SL‑325. Net proceeds from any sales under this program are expected to fund ongoing and planned clinical trials, advancement of additional product candidates, and general corporate and working capital needs, but the company is not obligated to sell any specific amount.
Shattuck Labs, Inc. reported that officer Stephen Stout received a stock option award for 351,400 shares of common stock at an exercise price of $4.75 per share on January 10, 2026. The option vests over time, with one quarter vesting on January 10, 2027 and the remaining three quarters vesting in equal monthly installments through January 10, 2030, contingent on his continued service.
On the same date, 4,153 shares of common stock were withheld at $4.75 per share in a transaction coded “F,” typically used for tax withholding, leaving Stout with 82,122 common shares held directly after the transaction.
Shattuck Labs, Inc. Chief Business Officer Casi DeYoung reported an equity award and a share disposition. On January 10, 2026, DeYoung was granted a stock option to purchase 381,600 shares of common stock at an exercise price of $4.75 per share. According to the vesting terms, one quarter of the option vests on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to continued service. On the same date, 5,699 shares of common stock were disposed of at $4.75 per share, after which DeYoung directly owned 75,766 shares of common stock.
Shattuck Labs, Inc. reported an equity award to its Chief Technical Officer, Abhinav A. Shukla. On January 10, 2026, he received a stock option covering 315,500 shares of Shattuck Labs common stock at an exercise price of $4.75 per share, reported as a derivative security held directly.
The option has a long-term vesting schedule: one quarter of the shares will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, conditioned on his continued service with the company. The option expires on January 10, 2036, giving him a multi-year window to exercise once vested.
Shattuck Labs, Inc. reported an insider equity transaction by its Chief Medical Officer, Pandite Arundathy N. On January 10, 2026, she was granted an option to purchase 487,800 shares of common stock at an exercise price of $4.75 per share. The option vests over time: one quarter of the shares on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, contingent on her continued service.
On the same date, she disposed of 6,851 shares of common stock at $4.75 per share, and reported owning 199,414 common shares directly after this transaction.
Shattuck Labs, Inc. Chief Financial Officer Andrew R. Neill reported new equity compensation and a related share withholding. On January 10, 2026, he received a stock option to purchase 549,800 shares of Shattuck Labs common stock at an exercise price of $4.75 per share. According to the vesting terms, one quarter of the option will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, contingent on his continued service.
On the same date, 6,660 shares of common stock were disposed of at $4.75 per share in a transaction coded "F," which typically reflects shares withheld to cover taxes upon vesting or exercise. After this transaction, Neill directly beneficially owned 230,813 shares of common stock and 549,800 stock options.